

The company has released voluntary disclosures since 2015 in accordance with the EFPIA Code of Practice

Grifols discloses transfers of value made to European healthcare professionals and healthcare organizations in 2020

- In line with its commitment to transparency, Grifols has disclosed for the sixth consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the EFPIA's scope, including Spain.
- In 2020, Grifols made transfers of value in Europe amounting to Euro 13.4 million. This fell by 14% due to the restrictions imposed by the pandemic, which resulted in the cancellation of numerous scientific events or their transformation into virtual meetings. Transfers of value related to R&D amounted to Euro 11.34 million, representing 84.4% of the total and a similar amount to that reported in 2019.
- In Spain, the evolution in 2020 was similar to that registered in Europe. Transfers of value decreased by 15% to Euro 7.26 million. Those related to R&D accounted for 92% of the total amount and stood at Euro 6.67 million.
- Spain generated 54% of the group's total transfers in Europe in 2020 and 59% of those related to R&D.
- In 2020, Grifols made transfers of value to 163 healthcare professionals in Spain that amounted to Euro 153,425 (Euro 383,014 in 2019) and 47 healthcare organizations, which totaled Euro 436,969 (Euro 944,137 in 2019).
- The *EFPIA Code of Practice*, which promotes transparency in industry interactions with healthcare professionals, healthcare organizations and patient organizations, applies specifically to medicines. Nonetheless Grifols expands its scope to include transfers unrelated to medications, as well as to the company's three main divisions: Bioscience, Diagnostic and Hospital.
- In addition to Europe, Grifols applies this policy of transparency in the United States as required by the regulatory body (Centers for Medicare & Medicaid Services, CMS).
- All related information is public and available on the Grifols' corporate website: www.grifols.com

Information Published in Accordance with the EFPIA Code of Practice

Grifols has voluntarily committed to publishing, on its website and on any specific platform required by each country, information on transfers of value to health professionals and healthcare organizations corresponding to each reporting period. The company will keep this information publicly available for three years and conserve it for six years.

Depending on the type of activity, the published information includes: donations and subsidies; corporate contributions for events, such as membership fees for healthcare professionals and sponsorship agreements with healthcare organizations, as well as payments to third parties designated to manage the event on their behalf; fees paid for consulting services and projects; travel and accommodation expenses incurred in relation to any of the aforementioned activities; and payments and other transfers of value related to R&D activities.

Specifically, the code of conduct is applied in the following European countries: Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.

Media contacts:

España Raquel Lumbreras Raquel_lumbreras@duomocomunicacion.com Borja Gómez Borja_gomez@duomocomunicacion.com Duomo Comunicación – Grifols Press Office Tel. +34 659 57 21 85 / +34 650 40 22 25	International Brad Pick Grifols Corporate Communications Brad.pick@grifols.com Tel. +34 93 571 00 02
--	---

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced.

GRIFOLS

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com